Please assess the completion status of the following clinical trial:

Trial Title: AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Participants that met the following criteria were eligible.~Inclusion Criteria:~* Symptomatic malignant ascites resulting from advanced ovarian epithelial cancer (including fallopian tube and primary peritoneal adenocarcinoma) that required at least 3 previous therapeutic paracenteses at a frequency of 1 to 4 paracenteses per month for management.~* Platinum resistant disease defined by relapse or progression of disease during or after treatment, or drug intolerance.~* Topotecan- and/or liposomal doxorubicin-resistant disease defined by relapse or progression of disease during or after treatment, or drug intolerance.~Exclusion Criteria:~* Peritoneovenous or other type of shunt that was placed for the management of ascites~* Prior treatment with a VEGF or VEGF receptor inhibitor~* Uncontrolled hypertension~The above information is not intended to contain all considerations relevant to participation in a clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aflibercept (Type: EXPERIMENTAL): Participants with advanced ovarian epithelial cancer (including fallopian tube and primary peritoneal adenocarcinoma) treated with Aflibercept every 2 weeks until a criterion for treatment discontinuation was met

Based on this trial design, predict the completion outcome and termination type (if applicable).